Samsung Group Set To Enter Biosimilars Market With $1.9 Billion Investment

SEOUL - Samsung Group has ended years of exploration for new business realms beyond its traditional pipeline of semiconductors and electronics products; South Korea's leading conglomerate is set to enter the healthcare sector, particularly biosimilars and medical devices, with an initial investment of roughly $4.1 billion